Abstract: A semiconductor device package may include a substrate having an insulating layer with a patterned conductive layer formed thereon, the patterned conductive layer including at least a first pattern portion and a second pattern portion. The semiconductor device package may include a leadframe having a lead that is soldered to the substrate with solder provided in an opening between the first pattern portion and the second pattern portion and with the lead inserted into the opening.

Abstract: The invention involves a cell line which can express human mutated tissue-type plasminogen activator (TNK-TPA), and its preparation methods. The collection number of cell lines in this invention is CCTCC C200006. We first used a DNA fragment from the short arms of human group D or group G chromosomes or its homolog to construct a recombinant human source gene vector-TNK-TPA (collection number is CCTC m200032); TNK-TPA gene is then incorporated into the target site in the nucleolus organizing region (NOR) of human group D or G chromosomes in host cell line HT1080; of which the recombinant cell line is attained after screening. The recombinant cell line can be used for manufacturing protein.

Abstract: The invention relates to site-specific integrating expression vectors for therapy Hemophilia B and to methods of preparing them. A vector of the invention contains a human Factor IX gene in a vector constructed using as a chromosome targeting sequence a polynucleotide without any important physiological function-related gene homologous to DNA on the short arms of human group D and human group G chromosomes. The vector of the invention provides high stability of Factor IX expression, high expression efficiency, no immunogenicity and safety in use.

Abstract: The present invention provides a human source gene targeting sequence a gene vector and gene expression strategies. The invention includes the following: (1) Using a DNA sequence without important physiological function-related genes in the short arms of human group D, G chromosomes, or a DNA sequence sharing 50% or over 50% identity to the sequence selected from human D, G group chromosomes, as a targeting sequence for gene targeting and (2) Construction of a gene vector containing the targeting sequence. the nucleolus organizing region in D, G group chromosomes that is described above is used as the target site, the gene of interest is integrated into the short arms where the gene expresses actively in D,G group chromosomes of human cells. The present invention provides a novel gene targeting sequence by which the gene vector construction and gene expression strategies are realized. The gene expression strategies can be used for human gene therapy and for manufacturing protein.

Abstract: The present invention relates to a micro-holding pipette. The holding end of the micro-holding pipette is a oblique opening, i.e. the end surface of the opening of the holding end of the micropipette is at an acute angle with the ordinate axis of the holding end, which is less than 90°, and preferably is from 25° to 85°. The present invention advantageously allows piercing a pellucid zona from the side, that is not the obverse surface, of a ovum or embryo by a micro injection needle or assistant needle for incubating, and without the deformation of the ovum or embryo due to the pressure. It is beneficial to various micro-processes. The novel micro-holding pipette and its operation can significantly prevent damage to the embryo and improve the healthy growth of the embryo.

Abstract: The present invention deals with the leading sequence of human source gene, gene vector and gene expression strategies. The invention include the following: (1) Using DNA sequence without pivot physiological function-related gene in short arms of human group D, G chromosomes, or a DNA sequence sharing 50% or over 50% identity to the sequence select from human D, G group chromosomes as leading sequence for gene targeting; (2) Construct the gene vector containing the leading sequence above; (3) Nucleolus organizing region in D, G group chromosomes mentioned in the procedure(1) is used as the target site, the gene of interest is integrated into the short arms where the gene expresses actively in D, G group chromosomes of human cells. The present invention provides a novel gene leading sequence by which the gene vector construction and gene expression strategies are obtained. The gene expression strategies can be used for human gene therapy and manufacturing protein.

Abstract: The invention involves a cell line which can express human mutated tissue-type plasminogen activator (TNK-TPA), and its preparation methods. The collection No. of cell line in this invention is CCTCC C200006. We firstly use a DNA fragment from the short arms of human D, G group chromosomes or its homologous to construct a recombinant human source gene vector-TNK-TPA (collection number is CCTC m200032); TNK-TPA gene is then transferred into the target site of nucleolus organizing region (NOR) of human D, G group chromosomes in host cell HT1080 by the recombinant and the cell line is attained after screening, which can be used for manufacturing protein.

Abstract: The invention deals with the gene drugs for therapy Hemophilia B and its method of preparation. It contains human source gene vector-FIX recombinant constructed using DNA sequence as leading sequence of therapy gene without important physiological function-related gene on the short arms of human group D,G chromosomes or to which DNA sequence is homologous. This invention also provides the method of preparing gene drug. The therapy gene of gene drug for hemophilia B has a high stability of expression, safety, high expression efficiency and no immunogenecity.

Abstract: EXT2 polypeptides and DNA (RNA) encoding such enzyme and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such EXT2 in the development of treatments for to hereditary multiple exotoses and cancers, such as chondrosarcoma, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.